Re-evaluate use in the presence of thromboembolic disorder signs &/or symptoms. Evaluate to exclude papilledema or retinal vascular lesions before continuing treatment in those who develop acute impairment of vision, proptosis, diplopia, migraine. Monitor for anaphylactic & anaphylactoid reactions. Amenorrhea & anovulation may persist for periods up to 18 mth, in rare cases for longer periods, after administration for several times. Carry out breast & pelvic organ exam including Pap smear before use. Careful administration for patients w/ epilepsy, migraines, asthma, cardiac or renal dysfunction due to risk of fluid retention. Consider organic causes & carry out a diagnostic exam in case of breakthrough bleeding. Patients w/ mental depression history; diabetes. Body wt may increase. May affect laboratory tests [eg, levels of plasma gonadotropin, progesterone, estrogen (in female) & cortisol, urinary pregnanediol; glucose tolerance test]; endocrine & liver function tests; mask the onset of the climacteric symptom. Not recommended for treatment of secondary amenorrhea or dysfunctional uterine bleeding.